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  1. Introduction
As the industry focuses on better manufacturing efficiency, there is greater interest in identifying powder properties  
that directly influence tabletting in-process performance and final product quality.  Particle-size distribution is a critical  
primary particle characteristic of powders, but it is only one of many variables that impact bulk powder properties, which in 
turn dictate in-process behaviour and product quality1. Bulk property measurements can be an efficient way of accelerating 
and supporting process optimization studies because they quantify the net effect of all primary particle properties (e.g., size,  
shape, texture, surface energy and porosity), whether these can be measured directly or not. Furthermore, even if all primary 
particle  properties  that  influence  in-process  behaviour  could be measured,  the  mathematical  relationship between bulk 
powder behaviour and particle characteristics remains elusive and highly complex. Hence, the most effective way forward is  
to measure process relevant characteristics of the bulk powder. 
Tablet production can be divided into at least four discrete processes :
• Discharge from the hopper
• Flow into and through the feed frame
• Die filling
• Compression
Each of these processes subjects the powder to a specific set of environmental conditions (e.g., flow rates, stresses,  
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The  elements  of  quality  by  design  are  examined  and  a  consistent 
nomenclature  for  quality  by  design,  critical  quality  attribute,  critical  process 
parameter, critical material attribute, and control strategy is proposed. 
A process is well  understood when all critical sources of variability are 
identified and explained, variability is managed by the process, and product quality 
attributes can be accurately and reliably predicted over the design space. Quality by 
Design (QbD) is a systematic approach to development of products and processes 
that  begins  with  predefined  objectives  and  emphasizes  product  and  process 
understanding and process control based on sound science, statistical methods and 
quality  risk  management.  In  an  attempt  to  curb  rising  development  costs  and 
regulatory barriers  to innovation and creativity,  the FDA and ICH have recently 
started promoting QbD in the pharmaceutical industry. QbD is partially based on the 
application  of  multivariate  statistical  methods  and  a  statistical  Design  of 
Experiments  strategy  to  the  development  of  both  analytical  methods  and 
pharmaceutical  formulations.  The talk will  review the  basics  of  QbD with  case 
studies from the pharmaceutical industry
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and equipment surface properties), making different bulk properties more relevant at different stages. I would highlight the 
following as especially valuable:
• Dynamic flow properties (including Basic Flowability Energy, Specific Energy, Aerated Energy, and Flow Rate 
Index): to optimise the flow regime in the feed frame and the efficiency of die filling, to investigate the effect of  
paddle geometry, to assess the likelihood of attrition, segregation and agglomeration. 
• Shear  properties:  for  optimising  flow  from  the  feed  hopper,  where  shear  properties  of  powder–powder  and 
powder–wall are important. 
• Permeability  and  compressibility:  for  assessing  how  easily  the  powder  can  transmit  air  and  the  impact  of  
compression on the powder. Both characteristics are important during the filling and compression steps. 
Success in tabletting does indeed depend on many factors. It is important, for example, to control the flowabilty  
and compressibility of  the tabletting blend,  as  well  as  any tendency towards  segregation,  to  ensure  the  production of  
uniform tablets at the required rate. Particle size and particle size distribution are recognised as critical material attributes 
because they are known to directly impact these properties, as well as others such as solubility and bioavailability, which 
may define clinical efficacy as highlighted in ICH Q6A. 
As analytical  techniques  evolve,  however,  it  is  becoming easier  to  identify other  parameters  that  also  impact  
behavior in the tablet press. Highlighting particle shape, a parameter that, like particle size, is known to affect powder  
flowability and segregation.  In  the past,  shape information was gathered by microscopy,  but  the advent  of  automated  
imaging has made it much faster and easier to access statistically relevant data. Such information forms a foundation for  
scientific investigation of the impact of shape and supports the development of more successful tabletting blends. 
2. QbD approaches to tabletting and granulation processes 
QbD calls for product quality to be 'designed in' rather than tested for in postproduction. It requires a detailed 
understanding of all the factors that can impact product quality and clinical efficacy, including those related to the materials  
employed and the process itself. Traditionally, it has been assumed that raw materials and intermediates can be suitably  
qualified and the process can be fixed, resulting in a consistent high-quality product2. However, this is only achieved by 
knowing what material properties need to be qualified. While particle size distribution is important, there are many other  
particle properties that rarely feature in the specification, but that can be as influential as particle size, such as particle shape  
and particle surface roughness3. Excluding these properties from the quality specification allows variation in raw materials 
to go undetected, resulting in variable in-process performance and product quality. Adopting a QbD approach requires an 
acceptance that raw materials are likely to vary batch to batch, while simultaneously demonstrating a good grasp of how to  
configure the process settings within the 'control space' to accommodate the unavoidable variation in material properties, 
and ultimately achieve consistent product with the desired attributes. 
Considering a granulation process as an example, this might conventionally be defined in the following terms:  
process for A minutes at an impeller speed of B rpm, whilst adding C% of water at a consistent addition rate. Processing 
conditions are essentially fixed and applied to each new batch of feed. This means that there is little flexibility to respond to 
variability arising from any source, such as a new batch of excipient or inadequate control of an upstream operation, for  
example. Furthermore, problems are usually detected only when granulation is complete. 
QbD places emphasis on controlling process output, rather than the fixed definition of operating conditions. For 
granulation, the process definition might change to: manipulate impeller speed, amount of water, and/or processing time, to  
produce granules with these specific properties. Adopting this approach, however, relies on being able to identify those 
specific properties—the criteria for success—and also learning how to control them. 
In the same way, in tabletting, a QbD approach would focus on the defining characteristics of the finished product, 
such as content uniformity and dissolution or disintegration properties. Process development then works back from that  
point, identifying all the factors that influence these properties. 
Successful implementation of QbD relies on understanding both the process and product in detail 2. The focus is on 
fully evaluating the impact of all variables that influence product quality, and learning how to control them effectively,  
rather than just identifying a manufacturing route that works. QbD extends through to control of the commercial process so 
it serves to highlight areas where real-time monitoring can be beneficially applied to meet processing targets. 
One important feature of particle size analysis is that, unlike many analytical techniques, it is already a proven  
technology for  real-time plant  monitoring.  In  granulation processes,  for  example,  both in-line probes based on spatial  
particle velocimetry and on-line laser diffraction particle size analysers are regularly used for real-time measurement. Both  
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enable the continuous tracking of particle size growth during the granulation process towards an established endpoint. 
Endpoint detection is a notoriously difficult aspect of granulation so this ability to continuously monitor particle  
size is extremely useful when manufacturing to meet a defined output, as advocated by QbD. In addition, however, real-time 
measurement is extremely valuable during design space scoping studies because it enables rapid and reliable assessment of 
the impact of a change in operating conditions. Continuous particle-size measurement can therefore accelerate and improve 
the process development studies associated with QbD1. 
3. Key challenges in understanding particle attributes in a tabletting and granulation process
The bulk properties that define process ability depend on a wide array of particle attributes, such as particle size  
and shape, roughness, surface charge, density and porosity. Learning how to control tabletting and granulation processes  
relies, in part, on understanding the relationships between particle attributes and bulk powder properties4,5. 
This is an area of specific interest and involved in a number of experimental studies, with industrial partners, to  
investigate,  for example,  the influence of particle  size and shape,  and of  surface charge, on powder flowability,  shear  
properties and bulk parameters, such as compressibility and permeability6.7. 
Because QbD places emphasis on thoroughly understanding the impact of all processing variables, it may call for 
information that  is  not  easily accessed using conventional  testing methods. As a result,  the implementation of QbD is 
encouraging  the  pharmaceutical  industry to  adopt  new analytical  technologies  as  they become available(8).  One such 
technology  is  morphologically  directed  imaging,  which  can  combine  imaging  technology  with  spectroscopy,  such  as  
Raman, to provide chemical identification alongside size and shape measurement. It allows different particles in a dispersed  
sample, often initially screened on the basis of size or shape, to be reliably identified as specific chemical entities. 
A conventional  way to assay a tablet  is  to dissolve it  and carry out  high-performance liquid chromatography 
analysis. This gives an averaged measure of the concentration of the active that can be used to assess dose consistency, but it  
provides no information about the size of discrete active particles that are delivered to the body as the tablet disintegrates 9. 
In contrast, applying morphologically directed imaging to a disintegrated tablet sample allows differently sized elements of  
the  resulting powder  to  be  precisely identified  as  active  or  excipient.  This  not  only generates  useful  information  for 
engineering sophisticated drug delivery profiles,  but  also provides  evidence to  support  claims of  bioequivalence for  a  
generic product
4. Challenges in bulk powder attributes
Pharmaceutical  industry's  ability to understand how bulk powder properties impact process behavior has  been 
constrained  by  a  lack  of  reliable  bulk  powder  property  data.  The  reproducible  measurement  of  defining  powder  
characteristics, such as flowabilty, has long been a goal, but the results have been mixed. Traditional techniques, such as 
flow through an orifice and tapped density methods, are not ideal for the extended, detailed experimental work required to 
support QbD11. Shear-cell measurements are ideal for understanding flow in hoppers, but are less useful for understanding 
lower stress processes, such as mixing, filling and aerosolization. Here, different measurement techniques are required. 
Powder testing has developed considerably in the past decade, including the introduction of dynamic testing12. 
Dynamic characterization reproducibly and directly measures powder flowabilty, for conditioned powders and for those that  
are  consolidated  or  aerated,  thereby  generating  reliable  and  valuable  information  for  process  development.  Used  in 
combination  with  bulk  and  shear  property  measurement,  dynamic  testing  enables  the  kind  of  multifaceted  powder 
characterization required to fully rationalise in-process behavior. 
With these techniques in place, it is now possible to develop a detailed understanding of the way bulk properties 
influence tabletting, granulation and many other frequently employed unit operations. This type of knowledge development 
remains a  work in  progress,  but  the goalposts shift  too13.  Faster  tabletting speeds are one example,  but  the long-term 
objectives of continuous production in integrated manufacturing suites adds another layer of complexity, requiring testing 
strategies that provide the deepest and most comprehensive information. 
5. Best practices in application of QbD to tableting and granulation
QbD relies heavily on engineering an optimized, well-understood process. It is therefore important, from the outset, 
to work out how to gather analytical data that will accurately reflect process performance. Effective powder handling is  
central  to  the  success  of  tableting,  granulation and  a wide  range of  other  pharmaceutical  unit  operations.  Appropriate 
powder characterization techniques are, therefore, an essential prerequisite14. 
The number of powder testing techniques available reflects both the importance of such testing and its difficulties.  
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When  choosing  which  techniques  to  apply for  QbD studies,  I  would  suggest  assessing  against  a  number  of  criteria  
including: 
• reproducibility and sensitivity 
• process relevance 
• ease of use. 
One of the biggest challenges for those applying QbD is how to access and gather the necessary information. The  
full implementation of QbD demands a comprehensive understanding of process and product, and the identification of an  
effective control strategy for the manufacturing process15. Choice of analytical instrumentation is therefore crucial. 
With well-established techniques such as laser diffraction particle-size measurement, customers can rightly expect  
the highest levels of automation and analytical productivity. Some systems can extend the efficiencies of dry measurement 
to more samples and combine rapid measurement times with assured data quality, to push analytical productivity to high 
levels for all users. 
Of  equal  importance,  however,  are  continuous  laser  diffraction  particle  size  analyzers  that  offer  real-time 
measurement  for  pilot-scale  studies  and  commercial  plant  monitoring  and  control.  These  systems  can  significantly 
accelerate  QbD  studies.  Running  a  pilot  plant  with  real-time  monitoring  in  place  enables  consistent  control  at  the  
experimental conditions of interest and makes the impact of changes in operating variables instantly obvious. 
For some types of  analysis,  the  technology is  newer,  but  it  is  vital  to  recognize  what  can  now be achieved. 
Returning to the example of morphologically directed imaging, these systems involve considerable investment but can 
deliver significant value over the long term. Being able to measure not just size and shape but also the distribution of  
different chemical species within a dispersed sample, such as a disintegrated tablet, can be invaluable when trying to really 
understand how the process works and how to optimize it16. 
5. Conclusion
A combination of analytical and statistical methods could be used to improve a tablet tabletting process guided by 
quality by design (QbD) principles. A solid dosage form product was found to intermittently exhibit bad taste. A suspected 
cause was the variability in tabletting thickness which could lead to the subject tasting the active ingredient in some tablets .
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